Myelodysplasia and the leukemias

Disease-a-Month

Volumn 43, Issue 8, 1997, Pages 507-597

  Jacobs, Peter ^a,b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CLADRIBINE; CORTICOSTEROID; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; HEMOPOIETIC GROWTH FACTOR; HYDROXYUREA; IDARUBICIN; INTERFERON; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER THERAPY; CHRONIC GRANULOCYTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; HEMATOPOIESIS; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; REVIEW; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; FEMALE; IMMUNOLOGY; MALE; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84866476464     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(97)90027-4     Document Type: Review

References (184)

1. Downey H, editor. Handbook of hematology. New York: Hafner; 1965.
2. Bird AR, Jacobs P, Shuttleworth M. Bone marrow examination in clinical practice. Hematol Rev 1995;9:111-39.
3. Wilkins BS. Histology of normal haemopoiesis: bone marrow histology I. J Clin Pathol 1992;45:645-9.
4. Dexter TM, Alien TD, Lajtha L.G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977;91:335-44.
5. Tavassoli M. Marrow adipose cells and hemopoiesis: an interpretative review. Exp Hematol 1984;12:139-46.
6. Jacobs P. Bone marrow failure: pathophysiology and management. Dis Mon 1995;41:201-92.
7. Boggs DR. The hematopoietic microenvironment. N Engl J Med 1980;302:1359-60.
8. Spangrude GJ. Characteristics of the hematopoietic stem cell compartment in adult mice. Int J Cell Cloning 1992;10:277-85.
9. Janssen WE. Hematopoiesis: an overview. Hematol Rev 1992;5:157-78.
10. Gordon MY, Amos TAS. Stochastic effects in hemopoiesis. Stem Cells (Dayt) 1994;12:175-9.
11. Zipori D. Stromal cells from the bone marrow: evidence for a restrictive role in regulation of hemopoiesis. Eur J Haematol 1989;42:225-32.
12. Pantel K, Nakeff A. The role of lymphoid cells in hematopoietic regulation. Exp Hematol 1993;21:738-42.
13. WHO-IUIS Nomenclature Subcommittee on Interleukin Designation: Nomenclature for secreted regulatory proteins of the immune system (interleukins). Blood 1992;79:1645-6.
14. Moore MAS. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 1991;78:1-19.
15. Nicola NA. Cytokine pleiotropy and redundancy: a view from the receptor. Stem Cells (Dayt) 1992;12(Suppl 1):3-14.
16. Kehrl JH. Hematopoietic lineage commitment: role of transcription factors. Stem Cells (Dayt) 1995;13:223-41.
17. Morgan GJ, Wiedemann LM. The clinical application of molecular techniques in Philadelphia-positive leukaemia. Br J Haematol 1992;80:1-5.
18. Dorée M, Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J 1994;8:1114-21.
19. Cohen JJ. Apoptosis: physiologic cell death. J Lab Clin Med 1994:124:761-5.
20. Blazsek I, Liu XH, Anjo A, Quittet P, Comisso M, Kim-Triana B, et al. The hematon, a morphogenetic functional complex in mammalian bone marrow, involves erythroblastic islands and granulocytic cobblestones. Exp Hematol 1995:23:309-19.
21. Verfaillie CM. Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood 1992;79:2821-6.
22. Frenette PS, Wagner DD. Adhesion molecules. I, II. N Engl J Med 1996;334:1526-9, 335:43-5.
23. Frenette PS, Wagner DD. Adhesion molecules. I, II. N Engl J Med 1996;334:1526-9, 335:43-5.
24. Gordon MY. Human haemopoietic stem cell assay. Blood Rev 1993;7:190-7.
25. Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991;78:55-62.
26. Jacobs P, Novitzky N. Acquired aplasia of the bone marrow. Hematology 1996;1: 59-64.
27. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995:85:3636-45.
28. Chomienne C, Fenaux P, Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 1996:10:1025-30.
29. Doll DC, List AF. Myelodysplastic syndromes: introduction. Semin Oncol 1992;19: 1-3.
30. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. BrJ Haematol 1992;82:358-67.
31. Bader-Meunier B, Miélot F, Tchernia G, Buisine J, Delsol G, Duchayne E, et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. Br J Haematol 1996;92:344-50.
32. List AF, Jacobs A. Biology and pathogenesis of the myelodysplastic syndromes. Semin Oncol 1992:19:14-24.
33. Forman SJ. Myelodysplastic syndrome. Curr Opin Hematol 1996;3:297-302.
34. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996:88:4275-87.
35. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes: the French-American-British (FAB) Co-operative Group. Br J Haematol 1982;51:189-99.
36. Bartl R, Frisch B, Baumgart R. Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies. Leuk Res 1992:16:15-33.
37. Galton DAG. The myelodysplastic syndromes, I: what are they? II: classification. Scand J Haematol 1986;36(Suppl 45): 11-20.
38. Third MIC Cooperative Study Group. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapyrelated myelodysplastic disorders. Cancer Genet Cytogenet 1988;32:1-10.
39. Mufti GJ. Chromosomal deletions in the myelodysplastic syndrome. Leuk Res 1992;16:35-41.
40. Rosati S, Anastasi J, Vardiman J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol 1996;33:111-26.
41. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8.
42. Nagai K, Kohno T, Chen YX, Tsushima H, Mori H, Nakamura H, et al. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome. Leuk Res 1996;20:563-74.
43. Greenberg PL. Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol 1996;33:163-75.
44. Colombat PH, Renoux M, Lamagnere JP, Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer 1988;61:1075-81.
45. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33:150-62.
46. Knottenbelt E, Jacobs P, Wilson EL. A prospective analysis of prognostic factors in the myelodysplastic syndromes. S Afr Med J 1990;77:69-74.
47. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425-33.
48. Rubio-Felix D, Giraldo P, Franco E, Gimeno J, Giralt M. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems. Hematol Oncol 1995;13:139-52.
49. Gonzalez Manso AI, Marcilla AG, Barreiro E, Gilsanz F. Cytohematologic and cytogenetic prognostic factors at diagnosis and in the evolution in 46 primary myelodysplastic syndromes. Cancer Genet Cytogenet 1992;61:174-82.
50. Saba HI. Myelodysplastic syndromes in the elderly: the role of growth factors in management. Leuk Res 1996;20:203-19.
51. Ferrero D, Bruno B, Pregno P, Stefani S, Larizza E, Ciravegna G, et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 1996;20:867-76.
52. Hamblin TJ. Intensive chemotherapy in myelodysplastic syndromes. Blood Rev 1992;6:215-9.
53. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996;88:358-65.
54. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994;13:763-9.
55. Southam CM, Craver LF, Dargeon HW, Burchenal JH. A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions. Cancer 1951;4:39-59.
56. Sayers GM, Rip MR, Jacobs P, Klopper JML, Karabus CD, Rosenstrauch WJ, et al. Epidemiology of acute leukaemia in the Cape Province of South Africa. Leuk Res 1992;16:961-6.
57. Clurman BE, Roberts JM, Groudine M. Deregulation of cell cycle control in hematologic malignancies. Curr Opin Hematol 1996;3:315-20.
58. Jacobs P. Choice of needle for bone marrow trephine biopsies. Hematol Rev 1995;9:163-8.
59. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group. Br J Haematol 1976;33:451-8.
60. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-2.
61. Scott CS, Den Ottolander GJ, Swirksky D, Pangalis GA, Vives Corrons JL, De Pasquale A, et al. Recommended procedures for the classification of acute leukaemias. Leuk Lymphoma 1993;11:37-49.
62. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukemias: report of the workshop held in Leuven, Belgium, September 15-17, 1986. Cancer Genet Cytogenet 1988;30:1-15.
63. Keinänen M, Griffin JD, Bloomfield CD, Machnicki J, de la Chapelle A. Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med 1988;318:1153-8.
64. Biondi A, Rambaldi A. Molecular diagnosis and monitoring of acute myeloid leukemia. Leuk Res 1996;20:801-7.
65. Griffin JD, Löwenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood 1986;68:1185-95.
66. Johnson PR, Yin JAL. Optimising treatment for elderly patients with acute leukaemia. Hematology 1996;1:103-12.
67. Raza A, Preisler HD, Li YQ, Larson RA, Goldberg J, Browman G, et al. Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. Am J Hematol 1993;42:359-66.
68. Fagioli F, Cuneo A, Carli MG, Bardi A, Piva N, Previati R, et al. Chromosome aberrations in CD34-positive acute myeloid leukemia: correlation with clinicopathologic features. Cancer Genet Cytogenet 1993;71:119-24.
69. Morgan GJ, Shiach C, Potter M. The clinical value of detecting gene rearrangements in acute leukaemias. Br J Haematol 1994;88:459-64.
70. Bennett JM, Andersen JW, Cassileth PA. Long term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res 1991;15:223-7.
71. de Haes JCJM, Stiggelbout AM. Assessment of values, utilities and preferences in cancer patients. Cancer Treat Rev 1996;22(Suppl A):13-26.
72. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
73. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994;83:10-25.
74. Black DJ, Livingston RB. Antineoplastic drugs in 1990: a review (part II). Drugs 1990;39:652-73.
75. Robert J, Rigal-Huguet F, Hurteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematol Oncol 1992;10:111-6.
76. Prentice HG. The role of mitozantrone in the treatment of acute leukaemia. Acta Haematol 1987;78(Suppl 1):136-8.
77. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-7.
78. Bishop JF. Intensified induction and post-remission therapy for acute myeloid leukaemia. Hematology 1996;1:91-102.
79. Mayer RJ, Davis RB, Schiffer CA, Berg DT. Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331:896-903.
80. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990;76:1867-71.
81. Hale G, Waldmann H, for CAMPATH users. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1996;17:305-8.
82. Truitt RL, Johnson BD. Principles of graft-vs.-leukemia reactivity. Biol Blood Marrow Transplant 1995;1:61-8.
83. Gamberi B, Bandini G, Visani G, Rosti G, Cenacchi A, Motta MR, et al. Acute myeloid leukemia from diagnosis to bone marrow transplantation: experience from a single centre. Bone Marrow Transplant 1994;14:69-72.
84. Rogers P, Wood L, Jacobs P. In acute myeloblastic leukaemia (AML) non-purged marrow autografts (ABMT) give comparable results to T-depleted allogeneic transplants from matched siblings (BMT) [abstract 1008]. Proc Am Soc Clin Oncol 1994;13:308.
85. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995;16:499-506.
86. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217-23.
87. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996;334:1428-34.
88. Zack M, Adami HO, Ericson A. Maternal and perinatal risk factors for childhood leukemia. Cancer Res 1991;51:3696-701.
89. Kinlen LJ. The epidemiology of leukaemia in children. Proc R Coll Physicians Edinb 1991;21:125-9.
90. Cartwright RA. Lifestyle and leukaemia. Br J Cancer 1991;64:417-8.
91. Cacciola RR, Stagno F, Impera S, Assisi AR, Cacciola E Jr, Guglielmo P. Beta-1-integrin expression in adult acute lymphoblastic leukemia: possible relationship with the stem cell antigen CD34. Acta Haematol 1997;97:63-6.
92. Lilleyman JS, Hann IM, Stevens RF, Richards SM, Eden OB, Chessells JM, et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. Br J Haematol 1992;81:52-7.
93. Bradstock KF, Kirk J, Grimsley PG, Kabral A, Hughes WG. Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations. Br J Haematol 1989;72:512-8.
94. Kurec AS, Belair P, Stefanu C, Barrett DM, Dubowy RL, Davey FR. Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia. Cancer 1991;67:3081-6.
95. First MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of acute lymphoblastic leukemias: report of the workshop held in Leuven, Belgium, April 22-23, 1985. Cancer Genet Cytogenet 1986;23:189-97.
96. Champlin R, Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 1989;73:2051-66.
97. Razis E, Arlin ZA, Ahmed T, Feldman EJ, Puccio C, Cook P, et al. Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol 1994;91:171-4.
98. McKinney PA, Alexander FE, Cartwright RA, Scott CS, Staines A. Acute lymphoblastic leukaemia incidence in the UK by immunophenotype. Leukemia 1993;7: 1630-4.
99. Pui CH. Acute leukemia in children. Curr Opin Hematol 1996;3:249-58.
100. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukemia of childhood: molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol 1995;17:1-12.
101. Asselin BL, Ryan D, Frantz CN, Bernai SD, Leavitt P, Sallan SE, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res 1989;49:4363-8.
102. Vichi P, Tritton TR. Adriamycin: protection from cell death by removal of extracellular drug. Cancer Res 1992;52:4135-8.
103. Budman DR. New vinca alkaloids and related compounds. Semin Oncol 1992;19:639-45.
104. Bertino JR. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
105. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188-90.
106. Chessells JM, Bailey C, Richards SM, for the Medical Research Council Working Party on Childhood Leukaemia. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 1995;345:143-8.
107. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
108. Greaves M. Silence of the leukemic clone. N Engl J Med 1997;336:367-9.
109. Finklestein JZ, Miller DR, Feusner J, Stram DO, Baum E, Shina DC, et al. Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia: a report from the Childrens Cancer Group. Cancer 1994;73: 219-23.
110. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy. A Childrens Cancer Group report. J Clin Oncol 1993;11:520-6.
111. Smibert E, Anderson V, Godber T, Ekert H. Risk factors for intellectual and educational sequelae of cranial irradiation in childhood acute lymphoblastic leukaemia. Br J Cancer 1996;73:825-30.
112. Clarkson B, Ellis S, Little C, Gee T, Arlin Z, Mertelsmann R, et al. Acute lymphoblastic leukemia in adults. Semin Oncol 1985;12:160-79.
113. Durrant IJ, Richards SM. Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: report from the Medical Research Council Working Party on Adult Leukaemia. Br J Haematol 1993;85:84-92.
114. Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991;7:453-9.
115. Attal M, Biaise D, Marit G, Payen C, Michallet M, Vernant JP, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1995;86:1619-28.
116. Oh H, Gale RP, Zhang MJ, Passweg JR, Ino T, Murakami H, et al. Chemotherapy versus HLA-identical sibling transplants for adults with acute lymphoblastic leukemia in first remission. Blood [In press].
117. Kohn DB. Gene therapy for haematopoietic and lymphoid disorders. Clin Exp Immunol 1997;107:54-7.
118. Jacobs P, King HS, Dent DM. Chronic granulocytic leukaemia: a 10-year experience in the black, coloured and white populations of the south-western Cape Province. S Afr Med J 1983;63:879-82.
119. Cervantes F, López-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol 1996;57:286-91.
120. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med 1996;100:555-70.
121. Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, et al. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol 1996;106:442-8.
122. Enright H, McGlave PB. Chronic myelogenous leukemia. Curr Opin Hematol 1996;3:303-9.
123. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick H, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87:746-54.
124. Schmid C, Frisch B, Beham A, Jäger K, Kettner G. Comparison of bone marrow histology in early chronic granulocytic leukemia and in leukemoid reaction. Eur J Haematol 1990;44:154-8.
125. Spiers ASD. Clinical manifestations of chronic granulocytic leukemia. Semin Oncol 1995;22:380-95.
126. Kadam PR, Nanjangud GJ, Advani SH, Nair C, Banavali S, Gopal R, Saikia T. Chromosomal characteristics of chronic and blastic phase of chronic myeloid leukemia: a study of 100 patients in India. Cancer Genet Cytogenet 1991;51:167-81.
127. Eaves CJ. Chronic myeloid leukaemia: biology of chronic myeloid leukaemia. Br J Haematol 1992;82:199-200.
128. Lim SH, Coleman S. Chronic myeloid leukemia as an immunological target. Am J Hematol 1997;54:61-7.
129. Gomez GA, Sokal JE, Walsh D. Prognostic features at diagnosis of chronic myelocytic leukemia. Cancer 1981;47:2470-7.
130. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982;60:1298-304.
131. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49-61.
132. Cervantes F, Robertson JE, Rozman C, Baccarani M, Tura S, Gomez GA, et al. Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Br J Haematol 1994;87:293-300.
133. Hasford J, Ansari H, Pfirrmann M, Hehlmann R. Analysis and validation of prognostic factors for CML: the German CML Study Group. Bone Marrow Transplant 1996;17(Suppl 3):S49-54.
134. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19(Suppl 9): 1-10.
135. Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol 1993;85:203-4.
136. Saven A, Piro LD, Lemon RH, Figueroa ML, Kosty M, Ellison DJ, et al. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 1994;73:2953-63.
137. Spencer A, O'Brien SG, Goldman JM. Options for therapy in chronic myeloid leukaemia. Br J Haematol 1995;91:2-7.
138. Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J, et al. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood 1992;79:997-1002.
139. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-α therapy for chronic myelogenous leukemia. Am J Med 1995;99:402-11.
140. Biggs JC, Szer J, Crilley P, Atkinson K, Downs K, Dodds A, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992;80:1352-7.
141. Bacigalupo A, Gualandi F, Van Lint MT, Sessarego M, Frassoni F, Occhini D, et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transplant 1993;12:443-8.
142. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993;12:509-16.
143. Barrett A, Jiang YZ. Immune responses to chronic myeloid leukaemia. Bone Marrow Transplant 1992;9:305-11.
144. Bunjes D, Theobald M, Hertenstein B, Wiesneth M, Novotny J, Arnold R, et al. Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transplant 1995;15:713-9.
145. Porter DL, Antin JH. Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leuk Lymphoma 1995;17:191-7.
146. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graftversus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-6.
147. Mackinnon S, Hows JM, Goldman JM, Arthur CK, Hughes T, Apperley JF, et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990;18:421-5.
148. Cole CH, Rogers PCJ, Pritchard S, Phillips G, Chan KW. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994;14:937-42.
149. Butturini A, Keating A, Goldman J, Gale RP. Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 1990;335:1255-8.
150. 1)-negative PBPC in chronic myelogenous leukaemia. Br J Haematol 1996;95:213-4.
151. Barnett MJ, Eaves CJ, Phillips GL, Kalousek DK, Klingemann HG, Lansdorp PM, et al. Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. Bone Marrow Transplant 1989;4:345-51.
152. Foon KA. Chronic lymphoid leukemias: recent advances in biology and therapy. Stem Cells 1995;13:1-21.
153. La Civita L, Zignego AL, Monti M, Longombardo G, Greco F, Pasero G, et al. Type C hepatitis and chronic lymphocytic leukaemia. Eur J Cancer 1996;32A:1819-20.
154. Matutes E. Trisomy 12 in chronic lymphocytic leukaemia. Leuk Res 1996;20: 375-7.
155. Dascalescu C, Gressin R, Callanan M, Sotto JJ, Leroux D. t (11;14) (q13;q32): chronic lymphocytic leukaemia or mantle cell leukaemia? Br J Haematol 1996;95:572-3.
156. Cuneo A, De Angeli C, Roberti MG, Piva N, Bigoni R, Gandini D, et al. Richter's syndrome in a case of atypical chronic lymphocytic leukaemia with the t(11;14) (q13;q32): role for a p53 exon 7 gene mutation. Br J Haematol 1996;92:375-81.
157. Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis. Mayo Clin Proc 1992;67:349-53.
158. Geisler CH, Hou-Jensen K, Myhre Jensen O, Tinggaard-Pedersen N, Mørk Hansen M, Hansen NE, et al. The bone-marrow infiltration pattern in B-cell chronic lymphocytic leukemia is not an important prognostic factor. Eur J Haematol 1996;57: 292-300.
159. Geisler CH, Larsen JK, Hansen NE, Mørk Hansen M, Egelund Christensen B, Lund B, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78: 1795-802.
160. Schwonzen M, Pohl C, Steinmetz T, Seckler W, Vetten B, Thiele J, et al. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol 1993;83:232-9.
161. A conference on the morphologic, immunologic, and cytogenetic classification of the chronic (mature) B and T lymphoid leukemias: (MIC IV). Cancer Genet Cytogenet 1990;48:131-2.
162. Vescio R, Rosen L, Schmulbach E, Berenson J. Multiple myeloma and chronic lymphocytic leukemia. Curr Opin Hematol 1996;3:288-96.
163. Jewell AP, Yong KL. Regulation and function of adhesion molecules in B-cell chronic lymphocytic leukaemia. Acta Haematol 1997;97:67-72.
164. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995;91:341-4.
165. Apostolopoulos A, Symeonidis A, Zoumbos N. Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia. Eur J Haematol 1990;44:39-44.
166. Catovsky D, Fooks J, Richards S, for the MRC Working Party on Leukaemia in Adults. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival - a report from the MRC CLL 1 trial. Br J Haematol 1989;72:141-9.
167. Montserrat E, Rozman C. Chronic lymphocytic leukaemia treatment. Blood Rev 1993;7:164-75.
168. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
169. French Cooperative Group on Chronic Lymphocytic Leukaemia. Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986;1:1346-9.
170. Johnson S, Smith AG, Löffler H, Ösby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: the French Cooperative Group on CLL. Lancet 1996;347:1432-8.
171. Jacobs P, King HS. A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases. Blood 1987;69:1642-6.
172. Caguioa PB, Tansan S, McCaffrey RP. Chronic lymphocytic leukemia. Am J Med Sci 1994;308:196-200.
173. Österborg A, Passas AS, Anagnostopoulos A, Dyer MJS, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996;93:151-3.
174. Neal TF Jr, Tefferi A, Witzig TE, Su J, Phyliky RL, Nagorney DM. Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients. Am J Med 1992;93:435-40.
175. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996;124:311-5.
176. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994;12:748-58.
177. Melo JV, Catovsky D, Galton DAG. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia, II: patterns of evolution of "prolymphocytoid" transformation. Br J Haematol 1986;64:77-86.
178. Catovsky D, Matutes E, Brito-Babapulle V. Is T-cell CLL adisease entity [Letters]? Br J Haematol 1996;94:580.
179. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588-93.
180. SaxingerW, Blattner WA, Levine PH, Clark J, Biggar R, Hoh M, et al. Human T-cell leukemia virus (HTLV-I) antibodies in Africa. Science 1984;225:1473-6.
181. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332:1744-8.
182. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993;82: 1-14.
183. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 1997;89:256-60.
184. Freter CE, Cossman J. Angioimmunoblastic lymphadenopathy with dysproteinemia. Semin Oncol 1993;20:627-35.